---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-144204"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:08:29.754073+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Appoints Charles Schoch as Permanent CFO, Effective June 20, 2025

## Summary
- Charles Schoch, interim CFO since Jan 2024, promoted to permanent CFO; base salary increased to $440,000, target bonus 40%.
- Granted option to purchase 50,000 shares; 25% vests at one year, then ratably over 36 months.
- Schoch previously served as VP Finance and Corporate Controller; led capital raise of ~$86M in Q4 2024.
- Press release highlights upcoming BLA submission for CAN-2409 in localized prostate cancer.
- No family relationships or arrangements with other parties disclosed.

## SEC filing metadata
- accession: 0001193125-25-144204
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/0001193125-25-144204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/d915163d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-144204
- JSON: https://secwatch.observer/filing/0001193125-25-144204.json
- Plain text: https://secwatch.observer/filing/0001193125-25-144204.txt

## Key facts
- Executive change
  Charles Schoch was appointed as Chief Financial Officer at Candel Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 20, 2025, the board of directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) unanimously appointed Charles Schoch as the Company’s Chief Financial Officer, effective June 20, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000119312525144204/0001193125-25-144204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.